New Delhi: Drug major Lupin expects to launch over two dozen products in the US next fiscal but said its revenues in the market could be muted with competitors expected to launch rival products in its key categories. “We expect to launch around 25 products in the US in the next fiscal. The Mumbai-based drug firm launched four products in the US market during the third quarter ended 31 December. Lupin is in the process of building a portfolio of niche products, including respiratory devices, which are difficult to manufacture and therefore command higher prices. Its sales during the quarter stood at Rs4,404.9 crore as against Rs3,350.3 crore in the corresponding period of the preceding fiscal, up 31.5%, it added.

Source: Mint February 12, 2017 08:40 UTC